BTG has earned significant royalties from successfully commercialising a large number of healthcare products, from cephalosporin antibiotics to Magnetic Resonance Imaging (MRI). The company continues to derive royalties from out-licensed marketed products, some of which are shown in the table below.
|
Product |
Licensee |
Indication/Description |
|
BeneFIX® |
Wyeth |
The first recombinant Factor IX therapy approved for the treatment of haemophilia B |
|
Two-Part Hip Cup |
All major orthopaedic companies, including Zimmer Holdings Inc, Stryker Corporation, Smith & Nephew Inc and Biomet Inc |
Prosthetic hip joint replacement which allows an improved range of motion that helps to avoid dislocation |
|
Campath® |
Genzyme Corporation |
A humanised anti-lymphocyte antibody approved for treatment of B-cell chronic lymphocytic leukaemia |
|
Three-Part Knee |
Biomet Merck Ltd and Corin Ltd |
Unicompartmental knee joint replacement designed to give more freedom of movement similar to that of a natural knee |
|